Difference between revisions of "Team:British Columbia/Description"
Ahmedhatem (Talk | contribs) |
|||
| Line 61: | Line 61: | ||
</div> | </div> | ||
<div class = "row"> | <div class = "row"> | ||
| − | <p> Distributing metabolic pathways between microbial community members has shown significant potential for the large-scale production of complex, biologically-derived chemical products. Our goal is to address the challenge of regulating population dynamics in a synthetic microbial consortium, by improving the rate of production of naringenin and its pharmaceutically significant derivative, kaempferol, which has anti-cancer properties. This is done by distributing the synthesis of kaempferol between two E. coli strains and optimizing their relative proportions in co-culture. To optimize population dynamics for the production of kaempferol, we regulated the ratio of the two strains using GP2, a transcriptional inhibitor, under the control of a biosensor responsive to the pathway intermediate naringenin. This couples cell growth with the concentration of naringenin, allowing the co-culture to self-optimize based on pathway intermediate abundance. Using our system, we have demonstrated a novel way to optimize microbial polycultures for the synthesis of metabolically complex compounds. </p> | + | <p> |
| + | Distributing metabolic pathways between microbial community members has shown significant potential for the large-scale production of complex, biologically-derived chemical products. Our goal is to address the challenge of regulating population dynamics in a synthetic microbial consortium, by improving the rate of production of naringenin and its pharmaceutically significant derivative, kaempferol, which has anti-cancer properties. This is done by distributing the synthesis of kaempferol between two E. coli strains and optimizing their relative proportions in co-culture. To optimize population dynamics for the production of kaempferol, we regulated the ratio of the two strains using GP2, a transcriptional inhibitor, under the control of a biosensor responsive to the pathway intermediate naringenin. This couples cell growth with the concentration of naringenin, allowing the co-culture to self-optimize based on pathway intermediate abundance. Using our system, we have demonstrated a novel way to optimize microbial polycultures for the synthesis of metabolically complex compounds. | ||
| + | <img src="https://static.igem.org/mediawiki/2018/f/fa/T--British_Columbia--glucose-kaempferol-graphic.png"> | ||
| + | </p> | ||
| + | |||
| + | </body> | ||
| + | </html> | ||
Revision as of 01:31, 18 October 2018
Distributing metabolic pathways between microbial community members has shown significant potential for the large-scale production of complex, biologically-derived chemical products. Our goal is to address the challenge of regulating population dynamics in a synthetic microbial consortium, by improving the rate of production of naringenin and its pharmaceutically significant derivative, kaempferol, which has anti-cancer properties. This is done by distributing the synthesis of kaempferol between two E. coli strains and optimizing their relative proportions in co-culture. To optimize population dynamics for the production of kaempferol, we regulated the ratio of the two strains using GP2, a transcriptional inhibitor, under the control of a biosensor responsive to the pathway intermediate naringenin. This couples cell growth with the concentration of naringenin, allowing the co-culture to self-optimize based on pathway intermediate abundance. Using our system, we have demonstrated a novel way to optimize microbial polycultures for the synthesis of metabolically complex compounds.
